Germany’s Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business. The German life ...

Germany’s Merck MRK1.91%increase; green up pointing triangle KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics SWTX-0.06%decrease; red down pointing ...

Stokes also sees more at play than just a disagreement over trade deficits. Trump’s threats “are rooted in frustration with ...

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around $3.9 billion, expanding its portfolio of rare disease and cancer ...

to friction with European co-producers less squeamish about such things. Germany’s newest line vis-a-vis Saudi Arabia is that the monarchy will be allowed to buy more Eurofighters through ...

(Reuters) - Germany's Merck KGaA said on Thursday it is ... In 2015, Merck agreed to buy U.S. lab equipment supplier Sigma-Aldrich for $17 billion. Reuters reported in February that the companies ...

According to David-Wilp at the German Marshall Fund of the United States, Merz sees a need for Germany to lead on defense in Europe because “things have really undergone major change since ...

Germany's Merck KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer. The German ...